• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Diabetes: Intarcia pulls down $210M for drug-device combo| Wall Street Beat

Diabetes: Intarcia pulls down $210M for drug-device combo| Wall Street Beat

November 16, 2012 By MassDevice staff

MassDevice.com Wall Street Beat

Intarcia Therapeutics said it’s reeled in financing worth a total of $210 million to further its drug-device combination treatment for Type II diabetes.

The Hayward, Calif.-based company, which is moving its headquarters to Boston, said the cash will also help facilitate the move.

Intarcia is developing ITCA 650, a matchstick-sized, miniature osmotic pump inserted subcutaneously to deliver the drug exenatide for 1 year. The company is planning a Phase III trial of the technology early next year, according to a press release.

The funding round, which Intarcia claims is biotech’s largest in at least 25 years, involved a $160 million private placement and a $50 million debt round. Backers included existing investors New Enterprise Associates, New Leaf Venture Partners and Venrock and new investors The Baupost Group, Farallon Capital Management and "3 additional top-tier institutional investors based in Boston and New York," according to the release.

"With this landmark financing in place, we have fully preserved the vision for our company and our aim to bring potentially revolutionary clinical, economic and humanistic benefits to millions of diabetes patients around the world," chairman, president & CEO Kurt Graves said in prepared remarks.

Intarcia said it plans to keep its R&D and manufacturing operations in Hayward.

 OptiMedica raises $35 million
OptiMedica said it closed a $35 million financing round from all of its existing backers, including Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital. Proceeds will go toward commercializing its Catalys precision laser for cataract surgery.
Read more

 Cynosure discounts offering
Cynosure (NSDQ:CYNO) priced its 3.2 million-share public offering $20.50 per share, a 3.3% discount from its closing price yesterday of $21.20 per share. CYNO shares were trading at $21.78 today as of about 12:15 p.m., up 2.7% on the day.
Read more

 Allergan drops $350M on SkinMedica
Allergan (NYSE:AGN) agreed to acquire SkinMedica’s topical aesthetics skin care business for $350 million up front and another $25 million pegged to sales milestones. The buyout, expected to close later this year, does not include SkinMedica’s Colorescience aesthetic make-up line, which SkinMedica plans to spin out as a separate company.
Read more

 InspireMD delays $40M offering
InspireMD (OTC:NSPR) said it’s postponing a planned, $40 million public stock offering "based on recent adverse market conditions."
Read more

 Analysts’ ups and downs

  • AtriCure (NSDQ:ATRC): Piper Jaffray upgrades from "neutral" to "overweight" rating, increases price target from $6 to $10.
  • Baxter (NYSE:BAX): Barclays maintains “equal weight” rating, raises price target from $63 to $68; Leerink Swann reiterates “outperform” rating, raises price target to $74 from $70.
  • Varian Medical (NYSE:VAR): Benchmark Company initiates coverage with “buy” rating, $88 price target.

Filed Under: Biotech, Funding Roundup, News Well, Wall Street Beat Tagged With: Allergan, Cynosure Inc., InspireMD, Intarcia Therapeutics, OptiMedica Corp., SkinMedica

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy